Palvella Therapeutics announced positive Phase 3 results for QTORIN™ rapamycin treating microcystic lymphatic malformations, with NDA submission planned for late 2026 and potential FDA approval in early 2027. The company raised $230 million in financing to support U.S. launch readiness and ongoing trials for other rare skin and vascular diseases. Key trials for cutaneous venous malformations and angiokeratomas are set to start soon, expanding their pipeline. Palvella ended 2025 with $58 million cash and a net loss of $41.7 million, reflecting increased R&D and administrative expenses as it advances clinical programs.
Shirofune has introduced Walmart Connect, an integration that allows advertisers and agencies to manage Walmart retail media campaigns alongside other digital channels within a single platform. This automation reduces manual bid adjustments and repor...
Purecore Metals Inc. has signed a non-binding letter of intent with Skyharbour Resources to acquire an option to earn up to 100% interest in the Yurchison uranium property in Saskatchewan's Athabasca Basin. The property covers over 35,000 hectares an...
Point completed a $508.6 million rated asset-backed securitization of its Home Equity Investment (HEI) assets, marking the largest transaction ever in the HEI asset class. The deal attracted over 30 institutional investors and priced at significantly...
The global reactive hot melt adhesives market is projected to grow from $2.02 billion in 2025 to $4.29 billion by 2035, at a CAGR of 7.72%. Growth is driven by regulations limiting solvent-based adhesives, increased use of polyurethane adhesives in a...
Industrial Development Funding (IDF) and Oaktree have committed $1.7 billion to support Bloom Energy's fuel cell technology for building AI cloud infrastructure for Nebius. This project will provide dedicated behind-the-meter power to meet the high c...
